In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US device tax – industry sees more traction for repeal of “bad policy”

This article was originally published in Clinica

Executive Summary

The drive to dismantle the 2.3% excise tax on sales of devices in the US has not lost any steam since it took effect on 1 January, in fact the pressure is picking up. A coalition of industry groups has increased their efforts to highlight the potential and actual damage to the US industry base to congressmen, and new bills have been introduced into Congress this year by legislators who are alive to the dangers.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT100043

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel